CRISPR Therapeutics AG (CRSP) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -2642.3% | -18933.6% | -16569.8% |
| 2024 | -215.0% | -1333.0% | -1046.4% |
| 2023 | 64.8% | -60.1% | -41.5% |
| 2022 | -25186.7% | -154394.7% | -149122.7% |
| 2021 | 88.9% | 40.9% | 41.4% |
Download Data
Export CRSP earnings history in CSV or JSON format
Free sign-in required to download data
CRISPR Therapeutics AG (CRSP) Earnings Overview
As of March 2, 2026, CRISPR Therapeutics AG (CRSP) reported trailing twelve-month net income of -$488M, reflecting -0.5% year-over-year growth. The company earned $-5.35 per diluted share over the past four quarters, with a net profit margin of -165.7%.
Looking at the long-term picture, CRSP's historical earnings data spans multiple years. The company achieved its highest annual net income of $378M in fiscal 2021.
CRISPR Therapeutics AG is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), CRSP has room to improve margins relative to the peer group. Compare CRSP vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$582M | -58.8% | -$665M | $-6.47 | -16569.8% | -18933.6% |
| 2024 | -$366M | -138.4% | -$467M | $-4.34 | -1046.4% | -1333.0% |
| 2023 | -$154M | +76.4% | -$223M | $-1.94 | -41.5% | -60.1% |
| 2022 | -$650M | -272.2% | -$673M | $-8.36 | -149122.7% | -154394.7% |
| 2021 | $378M | +208.3% | $374M | $4.70 | 41.4% | 40.9% |
| 2020 | -$349M | -621.8% | -$354M | $-5.29 | -48520.9% | -49295.5% |
| 2019 | $67M | +140.5% | $47M | $1.17 | 23.1% | 16.1% |
| 2018 | -$165M | -141.4% | -$159M | $-3.44 | -5281.1% | -5087.8% |
| 2017 | -$68M | -194.6% | -$65M | $-1.71 | -166.7% | -157.7% |
| 2016 | -$23M | +10.2% | -$68M | $-1.89 | -449.3% | -1319.3% |
See CRSP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRSP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CRSP vs AGIO
See how CRSP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CRSP growing earnings?
CRSP EPS of $-5.35 reflects slowing growth at -0.5%, below the 5-year CAGR of N/A. TTM net income is $-488M. Expansion rate has moderated.
What are CRSP's profit margins?
CRISPR Therapeutics AG net margin is -165.7%, with operating margin at -189.3%. Below-average margins reflect competitive or cost pressures.
How consistent are CRSP's earnings?
CRSP earnings data spans 2014-2025. The current earnings trend is -0.5% YoY. Historical data enables comparison across business cycles.